Immunogenicity in intravitreal anti-VEGF therapy: a call for balance and maturity in evaluating safety profiles

Piergiorgio Neri^{1

2}, Yanny Perez Jimenez³, Francesco Pichi^{3

4}

Affiliations

¹ The Eye Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. pg.neri@gmail.com.
² Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, Cleveland, OH, USA. pg.neri@gmail.com.
³ The Eye Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
⁴ Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, Cleveland, OH, USA.

Editorial

Piergiorgio Neri et al. Int Ophthalmol. 2024.

. 2024 Dec 5;44(1):445.

doi: 10.1007/s10792-024-03374-5.

Piergiorgio Neri^{1

2}, Yanny Perez Jimenez³, Francesco Pichi^{3

4}

¹ The Eye Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. pg.neri@gmail.com.
² Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, Cleveland, OH, USA. pg.neri@gmail.com.
³ The Eye Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
⁴ Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, Cleveland, OH, USA.

No abstract available

Conflict of interest statement

Declarations. Conflict of interest: The authors have not disclosed any competing interests.

1. Monés J et al (2021) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab. Ophthalmology 128:1050–1059 - DOI - PubMed
1. Matsumoto H et al (2024) Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular AMD. Jpn J Ophthalmol 68:531–537 - DOI - PubMed - PMC
1. Cozzi M et al (2024) Sterile intraocular inflammation associated with faricimab. JAMA Ophthalmol 142:1028–1036 - DOI - PubMed - PMC
1. American Academy of Ophthalmology. Post-marketing safety updates on brolucizumab. Accessed 2024
1. Regeneron Pharmaceuticals. Aflibercept safety profile: clinical trials and real-world evidence. Accessed 2024